Business, energy, technology, markets and global industry news from Business News Today

resmetirom

PharmaDeviceNews resmetirom
Ribo and Madrigal have advanced their first siRNA drug candidate for MASH into IND-enabling studies, highlighting the growing role of gene-silencing therapies in liver disease treatment. Representative image.
Pharma & Biotech

Madrigal expands MASH strategy as first Ribo siRNA candidate enters IND preparation

Discover why Ribo and Madrigal’s first nominated siRNA candidate could reshape genetically targeted and combination treatment strategies in MASH.

Read More
Representative image of AI-enabled liver disease research, reflecting how insitro’s CTRO-1013 MASH candidate is being studied for anti-fibrotic signals beyond liver fat reduction.
Pharma & Biotech

insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test

AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.

Read More
Pharma & Biotech

What Madrigal Pharmaceuticals, Inc.’s siRNA deal signals for the future of MASH treatment

Can Madrigal Pharmaceuticals, Inc. reshape MASH treatment with ARO-PNPLA3? Discover what this precision strategy means for the future.

Read More